Midatech Pharma (NASDAQ:MTP – Get Rating) and Longboard Pharmaceuticals (NASDAQ:LBPH – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Profitability

This table compares Midatech Pharma and Longboard Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for Midatech Pharma and Longboard Pharmaceuticals, as reported by MarketBeat.

Earnings and Valuation

This table compares Midatech Pharma and Longboard Pharmaceuticals' gross revenue, earnings per share and valuation.

Midatech Pharma has higher revenue and earnings than Longboard Pharmaceuticals.

Institutional and Insider Ownership

3.4% of Midatech Pharma shares are owned by institutional investors. Comparatively, 55.5% of Longboard Pharmaceuticals shares are owned by institutional investors. 6.8% of Longboard Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Midatech Pharma has a beta of 2.24, meaning that its stock price is 124% more volatile than the S&P 500. Comparatively, Longboard Pharmaceuticals has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Summary

Midatech Pharma beats Longboard Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Midatech Pharma

(Get Rating)

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

About Longboard Pharmaceuticals

(Get Rating)

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.